nature.com·4 min read·hard
New anti-fungal compounds 1PB1 and 45R from Streptomyces chrestomyceticus ADP4 target exo-β-1,3-glucanase and ergosterol biosynthesis in Candida albicans
S
Shukla, Jyoti
✦AI Summary
Researchers have identified two new anti-fungal compounds, 1PB1 and 45R, derived from Streptomyces chrestomyceticus that target Candida albicans. The study demonstrates that these compounds inhibit ergosterol biosynthesis and exo-β-1,3-glucanase, offering potential for new drug development.
Why it matters
Developing new anti-fungal treatments is critical as drug-resistant fungal infections pose an increasing threat to global health.
The Journal of Antibiotics ( 2026 ) Cite this article
sciencehealth
✦
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in